ETON
Eton Pharmaceuticals, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+35/100
Last price
54.77
▼ 0.85 (1.53%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
55.62
Day high
56.15
Day low
54.11
Volume
492.34K
Market cap
$1.57B
P/E (TTM)
136.93
52W range
14.27 – 66.37
Trailing performance
Returnvs SPY
1W
-7.47%
-9.4%
1M
-6.30%
-7.5%
3M
+51.42%
+46.9%
6M
+118.56%
+100.4%
YTD
+223.89%
+209.6%
1Y
+174.81%
+158.4%
3Y
+1,213.43%
+1,131.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ETON open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-105.05K
Net selling
Buy transactions
8
544.95K shares
Sell transactions
9
650.00K shares
Net transactions
+17
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
1.39M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 6, 26 | KREMPA DAVID Officer |
SELL | 4.17K | $229.41K | Direct |
| Oct 2, 26 | KREMPA DAVID Officer |
— | 10.52K | — | Direct |
| Aug 28, 26 | MAIER PAUL V Director |
SELL | 50.00K | $2.95M | Direct |
| Aug 28, 26 | MAIER PAUL V Director |
SELL | 50.00K | $2.95M | Direct |
| Aug 28, 26 | MAIER PAUL V Director |
CONVERSION | 50.00K | $189.00K | Direct |
| Aug 28, 26 | MAIER PAUL V Director |
CONVERSION | 62.50K | $280.38K | Direct |
| Aug 24, 26 | KREMPA DAVID Officer |
SELL | 25.00K | $1.63M | Direct |
| Aug 24, 26 | KREMPA DAVID Officer |
CONVERSION | 25.00K | $182.75K | Direct |
| Aug 20, 26 | BRYNJELSEN SEAN E Chief Executive Officer |
SELL | 100.00K | $6.09M | Direct |
| Jul 14, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 28.32K | $1.06M | Indirect |
| Jul 14, 26 | BRYNJELSEN SEAN E Chief Executive Officer |
CONVERSION | 227.50K | $274.00K | Direct |
| Jul 10, 26 | KREMPA DAVID Officer |
— | 10.00K | — | Direct |
| Jul 7, 26 | OPALEYE MANAGEMENT, INC. Beneficial Owner of more than 10% of a Class of Security |
SELL | 126.69K | $4.77M | Indirect |
| Jun 17, 26 | ADAMS JENNIFER MCKIE Director |
SELL | 50.00K | $1.62M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS JENNIFER MCKIE |
Director | 0 | Sale |
BRYNJELSEN SEAN E |
Chief Executive Officer | 961.19K | Sale |
GRUBER JAMES R |
Chief Financial Officer | 204.75K | Sale |
KREMPA DAVID |
Officer | 43.38K | Sale |
MAIER PAUL V |
Director | 59.74K | Sale |
OPALEYE MANAGEMENT, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
RIEDEL NORBERT G |
Director | 224.30K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$1.57B
Enterprise value$1.57B
Revenue (TTM)$105.59M
Gross profit$64.85M
EBITDA$25.18M
Net income$12.69M
EPS (TTM)$0.40
Free cash flow$6.58M
Total cash$26.84M
Total debt$29.23M
Book value / share$1.65
Shares outstanding28.58M
Float22.30M
Short % of float7.46%
Dividend yield0.00%
Beta (5Y)0.90
Valuation & profitability ratios
Trailing P/E136.93
Forward P/E21.23
PEG ratio—
Price / sales—
Price / book33.25
EV / revenue14.85
EV / EBITDA62.27
Gross margin61.41%
Operating margin35.77%
Profit margin12.02%
Return on equity35.97%
Return on assets11.86%
Debt / equity62.74
Current ratio1.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $79.95M | $39.01M | $31.64M | $21.25M | +104.9% |
| Operating revenue | $79.95M | $39.01M | $31.64M | $21.25M | +104.9% |
| Cost of revenue | $37.21M | $15.60M | $10.58M | $6.93M | +138.5% |
| Gross profit | $42.74M | $23.41M | $21.06M | $14.32M | +82.6% |
| Research & development | $7.76M | $3.25M | $3.32M | $4.00M | +138.6% |
| Selling, general & admin | $35.82M | $22.75M | $18.93M | $18.58M | +57.4% |
| Total operating expense | $43.58M | $26.01M | $22.25M | $22.58M | +67.6% |
| Operating income | -$844.00K | -$2.60M | -$1.19M | -$8.26M | +67.5% |
| Net interest income | -$3.71M | -$1.21M | $503.00K | -$761.00K | -206.7% |
| Pre-tax income | -$4.56M | -$3.81M | -$689.00K | -$9.02M | -19.7% |
| Tax provision | $43.00K | $15.00K | $247.00K | $0 | +186.7% |
| Net income | -$4.60M | -$3.82M | -$936.00K | -$9.02M | -20.4% |
| Net income to common | -$4.60M | -$3.82M | -$936.00K | -$9.02M | -20.4% |
| Basic EPS | -0.17 | -0.15 | -0.04 | -0.36 | -13.3% |
| Diluted EPS | -0.17 | -0.15 | -0.04 | -0.36 | -13.3% |
| EBIT | -$844.00K | -$2.60M | -$1.19M | -$8.26M | +67.5% |
| EBITDA | $3.20M | -$1.45M | -$291.00K | -$6.49M | +320.5% |
| Basic shares | 26.91M | 25.89M | 25.64M | 25.15M | +3.9% |
| Diluted shares | 26.91M | 25.89M | 25.64M | 25.15M | +3.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $25.94M | $14.94M | $21.39M | $16.30M | — | +73.7% |
| Cash & short-term investments | $25.94M | $14.94M | $21.39M | $16.30M | — | +73.7% |
| Accounts receivable | $11.76M | $5.36M | $3.41M | $1.85M | — | +119.3% |
| Inventory | $15.42M | $15.23M | $911.00K | $557.00K | — | +1.2% |
| Total current assets | $60.58M | $41.02M | $26.84M | $20.00M | — | +47.7% |
| Property, plant & equipment | $636.00K | $209.00K | $150.00K | $260.00K | — | +204.3% |
| Goodwill & intangibles | $30.88M | $34.88M | $4.74M | $4.75M | — | -11.5% |
| Total assets | $92.11M | $76.12M | $31.74M | $25.03M | — | +21.0% |
| Total current liabilities | $38.49M | $19.95M | $16.24M | $6.46M | — | +93.0% |
| Current debt | $8.79M | — | $5.38M | $1.03M | $1.42M | — |
| Long-term debt | $21.77M | $29.81M | — | $5.38M | $5.26M | -27.0% |
| Total debt | $31.02M | $29.92M | $5.40M | $6.52M | — | +3.7% |
| Total liabilities | $65.96M | $51.70M | $16.26M | $11.95M | — | +27.6% |
| Retained earnings | -$112.49M | -$107.89M | -$104.07M | -$103.13M | — | -4.3% |
| Shareholder equity | $26.15M | $24.43M | $15.48M | $13.08M | — | +7.1% |
| Working capital | $22.09M | $21.07M | $10.60M | $13.54M | — | +4.8% |
| Net tangible assets | -$4.72M | -$10.45M | $10.74M | $8.32M | — | +54.8% |
| Shares issued | 27.05M | 26.71M | 25.69M | 25.35M | — | +1.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$4.60M | -$3.82M | -$936.00K | -$9.02M | -20.4% |
| Depreciation & amortisation | $4.04M | $1.15M | $901.00K | $1.77M | +252.9% |
| Stock-based compensation | $5.51M | $3.17M | $3.14M | $4.22M | +74.2% |
| Change in working capital | -$859.00K | -$1.23M | $3.51M | $7.66M | +30.0% |
| Operating cash flow | $10.52M | $969.00K | $6.82M | $4.82M | +986.1% |
| Capital expenditure | -$333.00K | -$10.01M | -$775.00K | -$2.79M | +96.7% |
| Investing cash flow | -$333.00K | -$40.01M | -$775.00K | -$2.79M | +99.2% |
| Financing cash flow | $815.00K | $32.59M | -$957.00K | -$134.00K | -97.5% |
| Free cash flow | $10.19M | -$9.04M | $6.04M | $2.03M | +212.7% |
| End cash position | $25.94M | $14.94M | $21.39M | $16.30M | +73.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $37.59M | $24.27M | $21.28M | $22.46M | $18.93M | +54.9% |
| Operating revenue | $37.59M | $24.27M | $21.28M | $22.46M | $18.93M | +54.9% |
| Cost of revenue | $12.18M | $9.53M | $8.18M | $14.60M | $7.00M | +27.8% |
| Gross profit | $25.41M | $14.73M | $13.10M | $7.86M | $11.92M | +72.5% |
| Research & development | $993.00K | $1.88M | $1.78M | $1.11M | $3.71M | -47.0% |
| Selling, general & admin | $11.63M | $10.45M | $8.86M | $8.11M | $9.69M | +11.3% |
| Total operating expense | $12.62M | $12.32M | $10.64M | $9.22M | $13.40M | +2.4% |
| Operating income | $12.79M | $2.41M | $2.46M | -$1.36M | -$1.48M | +430.0% |
| Net interest income | -$1.08M | -$840.00K | -$1.05M | -$592.00K | -$1.04M | -28.1% |
| Pre-tax income | $11.72M | $1.57M | $1.41M | -$1.96M | -$2.52M | +644.5% |
| Tax provision | $140.00K | $20.00K | -$69.00K | -$28.00K | $66.00K | +600.0% |
| Net income | $11.58M | $1.55M | $1.48M | -$1.93M | -$2.58M | +645.0% |
| Net income to common | $11.58M | $1.55M | $1.48M | -$1.93M | -$2.58M | +645.0% |
| Basic EPS | 0.42 | 0.06 | 0.06 | -0.07 | -0.10 | +600.0% |
| Diluted EPS | 0.35 | 0.05 | 0.05 | -0.07 | -0.10 | +600.0% |
| EBIT | $12.79M | $2.41M | $2.46M | -$1.36M | -$1.48M | +430.0% |
| EBITDA | $14.18M | $3.54M | $3.48M | -$354.00K | -$470.00K | +300.0% |
| Basic shares | 27.64M | 27.29M | 26.94M | 26.89M | 26.89M | +1.3% |
| Diluted shares | 32.79M | 31.55M | 31.24M | 26.89M | 26.89M | +3.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.84M | $19.66M | $25.94M | $37.12M | $25.38M | +36.5% |
| Cash & short-term investments | $26.84M | $19.66M | $25.94M | $37.12M | $25.38M | +36.5% |
| Accounts receivable | $24.89M | $13.41M | $11.76M | $13.08M | $14.45M | +85.6% |
| Inventory | $10.14M | $14.47M | $15.42M | $16.86M | $23.79M | -29.9% |
| Total current assets | $68.60M | $53.24M | $60.58M | $72.00M | $68.44M | +28.8% |
| Property, plant & equipment | $1.47M | $673.00K | $636.00K | $613.00K | $342.00K | +117.8% |
| Goodwill & intangibles | $45.68M | $43.74M | $30.88M | $31.88M | $32.88M | +4.4% |
| Total assets | $115.81M | $97.71M | $92.11M | $104.51M | $101.68M | +18.5% |
| Total current liabilities | $45.12M | $44.18M | $38.49M | $44.18M | $38.60M | +2.1% |
| Current debt | $8.82M | $11.81M | $8.79M | $2.78M | $2.77M | -25.3% |
| Long-term debt | $19.08M | $18.94M | $21.77M | $27.59M | $27.41M | +0.7% |
| Total debt | $28.99M | $31.19M | $31.02M | $30.85M | $30.67M | -7.1% |
| Total liabilities | $69.22M | $67.09M | $65.96M | $81.38M | $77.72M | +3.2% |
| Retained earnings | -$99.36M | -$110.94M | -$112.49M | -$113.98M | -$112.05M | +10.4% |
| Shareholder equity | $46.59M | $30.61M | $26.15M | $23.13M | $23.96M | +52.2% |
| Working capital | $23.48M | $9.07M | $22.09M | $27.82M | $29.85M | +158.9% |
| Net tangible assets | $907.00K | -$13.12M | -$4.72M | -$8.75M | -$8.92M | +106.9% |
| Shares issued | 28.29M | 27.36M | 27.05M | 26.82M | 26.82M | +3.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $11.58M | $1.55M | $1.48M | -$1.93M | -$2.58M | +645.0% |
| Depreciation & amortisation | $1.39M | $1.13M | $1.02M | $1.01M | $1.00M | +22.5% |
| Stock-based compensation | $1.47M | $1.52M | $1.12M | $1.09M | $2.10M | -3.3% |
| Change in working capital | -$8.37M | $2.49M | -$17.37M | $10.45M | $6.17M | -436.0% |
| Operating cash flow | $7.25M | $7.41M | -$11.55M | $12.03M | $7.96M | -2.0% |
| Capital expenditure | — | -$15.07M | -$49.00K | — | — | — |
| Investing cash flow | $5.00K | -$15.07M | -$49.00K | -$284.00K | $0 | +100.0% |
| Financing cash flow | -$76.00K | $1.39M | $421.00K | $0 | $0 | -105.5% |
| Free cash flow | $7.26M | -$7.67M | -$11.60M | $11.74M | $7.96M | +194.7% |
| End cash position | $26.84M | $19.66M | $25.94M | $37.12M | $25.38M | +36.5% |
Options analytics
Put / call volume
0.25
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
35.00
-36.1% from spot
ATM implied vol
0.8%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
68
Contracts, this expiry
Put volume
17
Contracts, this expiry
Heaviest call OI
35.00
0 contracts
Heaviest put OI
40.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.43 | +126.3% |
| Mar 2026 | 0.14 | 0.14 | 0.0% |
| Dec 2025 | 0.20 | 0.19 | -5.0% |
| Sep 2025 | 0.16 | 0.04 | -75.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.37 | 2 | $42.21M | +87.9% |
| Next quarter | 0.44 | 2 | $46.36M | +117.8% |
| Current year | 1.40 | 2 | $149.71M | +87.3% |
| Next year | 2.58 | 2 | $219.91M | +46.9% |
Analyst targets & ownership
Mean target$71.00
High target$76.00
Low target$68.00
Implied upside29.63%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders4.87%
Held by institutions71.08%
Institutions holding235
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
56.04
-2.26% from price
SMA 20
56.40
-2.89% from price
SMA 50
55.12
-0.64% from price
SMA 100
44.90
+21.99% from price
SMA 200
32.50
+68.51% from price
EMA 12
55.76
-1.78% from price
EMA 26
56.00
-2.20% from price
EMA 50
53.41
+2.55% from price
RSI (14)
47.4
Neutral
MACD (12,26,9)
-0.24
Hist -0.53
ATR (14)
3.54
6.45% of price
Realised vol 30D
58.5%
Annualised
Bollinger upper
60.65
20, 2σ
Bollinger lower
52.15
20, 2σ
50 / 200 cross
Golden
55.12 vs 32.50
Trend bias
Above 200
+68.51%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.16
Less volatile than market
Correlation to SPY
0.03
Largely independent
Realised vol 30D
58.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.2%
Peak to trough
Max drawdown 5Y
-69.3%
Peak to trough
ATR 14
3.54
6.45% of price
Beta (reported)
0.90
5Y monthly, from filing
Short interest
Shares short
1.54M
Prior 1.43M
Change vs prior
+8.1%
Shorts adding
% of float
7.46%
Normal
% of shares out
5.40%
Against total outstanding
Days to cover
2.7
Liquid
Float
22.30M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 14, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Aug 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 28, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Jul 17, 26 | Canaccord Genuity | INITIATED | — | Buy |
| May 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Mar 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Mar 3, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Periodic Financial Reports
10-Q · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-05-19
Corporate Changes & Voting Matters
8-K · 2026-05-14
Headlines
Eton Pharmaceuticals Launches Impavido Capsules to Treat Leishmaniasis
MT Newswires · 9d ago
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
GlobeNewswire · 9d ago
Eton Pharmaceuticals Insider Sold Shares Worth $2,953,572, According to a Recent SEC Filing
MT Newswires · 40d ago
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
Insider Monkey · 40d ago
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
GlobeNewswire · 41d ago
Eton Pharmaceuticals Insider Sold Shares Worth $1,626,750, According to a Recent SEC Filing
MT Newswires · 44d ago
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Investor's Business Daily · 44d ago
Three Biotech Stocks Stick Out With Their Stellar Charts
Investor's Business Daily · 47d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.